Horizon Discovery’s (LSE: HZD) announcement on the identity of its new chief executive on Tuesday has been followed on Wednesday by a major drop in the share price of the gene editing company.
But the two are not linked, with the reason for Horizon’s stock value plummeting more likely the result of a separate announcement made by Abcam (AIM: ABC), another UK life science research tool specialist.
In mid-April, Abcam made a proposal to acquire Horizon at £1.81 a share, valuing the target firm’s worth at around £270 million ($368 million).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze